Continuous Biomanufacturing (CBM) of Large Molecule Drug Substances-Guidance

Background and Industry Overview

Continuous biomanufacturing (CBM) refers to the uninterrupted, end-to-end production of biologic drug substances, streamlining steps that traditionally require separate batch processing, testing, and refeeding. Unlike fed-batch systems, continuous processes integrate real-time testing, feeding, and production—reducing downtime and improving operational flexibility and efficiency.

This model significantly shortens production timelines, optimizes resource utilization, supports real-time quality monitoring, that can enable swift response to changes in market demand. It also opens new opportunities for innovative product development, not feasible with conventional methods.

Benefits of CBM include:

• What are the drivers to consider when moving to a CBM platform?
• Higher facility utilization
• Adaptable batch sizes
• Easier scalability
• Enhanced process control
• Lower energy consumption
• Improved scheduling adherence

Purpose and Objectives

This Guide serves as a practical roadmap for the design, development, and implementation of continuous and hybrid biomanufacturing platforms for large molecule drug substances, particularly recombinant proteins from mammalian cells. While CBM approaches may vary, most align under a converging framework that can support standardized global manufacturing.

This Guide details equipment considerations, regulatory compliance strategies, and practical deployment models to facilitate CBM adoption across various biopharmaceutical settings, including contract manufacturing.

Scope

Covering established and emerging concepts central to CBM, this Guide places an emphasis on real-world good manufacturing practice (GMP) applications and lifecycle management. Topics include:

• Control strategy development (e.g., risk assessment, process analytical technology (PAT), process modeling)
• Start-up and shutdown protocols
• In-line/at-line control models and sensor integration
• Hybrid versus full end-to-end CBM approaches
• Regulatory expectations and digital integration (artificial intelligence, the Internet of Things, the International Council for Harmonisation of Technical Requirements of Pharmaceuticals for Human Use (ICH) Q11, Q12)
• Cost optimization and supply chain benefits

Structure of the Guide

1. Introduction to CBM
   Explains the foundational goals and motivations for transitioning to CBM, highlighting industry-wide challenges and strategies for effective implementation
2. Regulatory and Quality Considerations
   This section explores how evolving regulations and global harmonization (e.g., ICH Q13) intersect with CBM. It outlines best practices for integrating advanced technology and risk-based approaches to ensure compliance and consistent product quality
3. Scientific and Technical Enablers of Continuous Biomanufacturing
   Focuses on the scientific principles that influence CBM design, including:
   1. Cell line behavior
   2. Formulation dynamics
   3. Critical quality attributes and critical process parameters
   4. Examples from case studies on process development
4. Integrated Continuous Biomanufacturing
   Discusses the design and operational advantages of integrated CBM platforms
   1. Rationales for adopting CBM
   2. Comparison of hybrid and full end-to-end systems
   3. Upstream and downstream process strategies
   4. Traceability, batch definitions, and lot management
   5. Real-world deployment scenarios
5. Facilities
   Details the equipment and technologies that enable CBM, including:
   1. Integration of process control devices
   2. In-process analytics
   3. Facility design for GMP compliance
   4. Challenges in retrofitting or building new CBM-ready facilities
6. Process Control and Validation Strategies
   Explores how CBM changes the validation and control paradigm:
   1. Implementation of PAT
   2. Integration of digital sensors and predictive control models
   3. Real-time release testing
   4. Addressing comprehensive validation and compliance approaches
   5. Digital twin systems to forecast product quality and manage dynamic interactions
7. Economic Justification Considerations
   Provides a deep dive into the financial implications of transitioning to CBM:
   1. Cost-benefit analysis and return on investment frameworks
   2. Capital investment and operational expense breakdown
   3. Long-term savings in labor, utilities, and materials
   4. Strategic investment planning for CBM adoption

Appendices Overview

• Appendix 1 – Case Studies: Practical examples of PAT implementation and control strategy design
• Appendix 2 – Predictive Modeling of a Continuous Process: Methodologies for model development in CBM environments
• Appendix 3 – Supplemental Technical Information: Charts, figures, and explanatory content referenced throughout the Guide
• Appendix 4 – References: Comprehensive citation of regulatory, academic, and industry sources
• Appendix 5 – Glossary: Definitions, acronyms, and terminology relevant to CBM

Learn more and Purchase Guide